Eisai Co. Ltd.

Leading Practices

• Eisai has dedicated a section of its new R&D center in India to Chagas disease and malaria. The company currently has two molecules for malaria and one for Chagas disease in its pipeline developed through collaborative research.
• Eisai has introduced an ATM Strategy in 2009 in which it disclosed ATM pricing policies based on affordability criteria, processes, standards, targets and has also defined the Index Countries covered by its program. This is a leading practice among the Japanese companies covered by Index 2010.

Changes Compared to Index 2008

• Eisai was not evaluated in Access to Medicine Index 2008.
• The company has stated that it plans to implement tiered pricing for an anti-epileptic product and has committed to implement tiered pricing for future Index Disease products especially for malaria and Chagas Disease.
• In 2008, the company launched research on malaria and Chagas disease.
• In 2009, the company significantly improved its ATM related policies and targets (please refer to the related leading practice).  

Suggested Areas for Improvement

• The company has low public disclosure on public policy positions, lobbying activities and marketing activities in the Index Countries.
• Disclosure about existing ATM initiatives in areas such as resources dedicated and terms and conditions of collaborations is also low.
• Eisai is not transparent on the registration and patent status of Index Disease products in the Index Countries.